GENERAL COMMENTS
This is an interesting study exploring the association with a specific class of benzodiazepine-associated hypnotics (zopiclone, zolpidem, zaleplon) with a specific group of hallucinations (tactile, olfactory, gustatory) in patients with affective and non-affective psychoses. Using a language analysis tool, the investigators were able to scan 43,339 medical records over a one year period (2014) and to pair mention of these hallucinations with mention of these drugs.0.75% of the sample had these hallucinations. The hypnotics in question were mentioned in 22.6% of the sample. There was a significant association of these hallucinations with these drugs although the direction of effects could not be determined. It is theoretically possible that the hallucinations led to insomnia for which these drugs (rather than other hypnotics) were prescribed. The association was strongest in the schizophrenia population and for olfactory and tactile hallucinations. I have no quarrel with this study but wonder why so many varieties of similar hypnotics are available for use in the UK and why such a large percentage of patients with psychosis (presumably treated with antipsychotic drugs) need additional hypnotics.
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GENERAL COMMENTS
The paper is of particular interest as it refers to z-hypnotics use in major European city population. The hypothesis is clearly described and well defined. All data is adequately gathered and analysed with conclusions drawn in an informative way. The only thing I miss in the discussion is the risk of zolpidem associated adverse drug reactions as related to subjects' sex with particular focus on women. If authors found this remark meaningfull it were of an importance to the reader. I suggest the manuscript acceptance for publication in BMJO.
VERSION 1 -AUTHOR RESPONSE
Response to Reviewer 1: Comment:"I have no quarrel with this study but wonder why so many varieties of similar hypnotics are available for use in the UK and why such a large percentage of patients with psychosis (presumably treated with antipsychotic drugs) need additional hypnotics."
Thank you for careful review of this manuscript and positive feedback. With regards to availability of hypnotics in the UK, PRN use of hypnotics is common in many medical and psychiatric inpatient settings. It is certainly interesting to hear that this is not the case worldwide.
Response to Reviewer 2: Comment: "The only thing I miss in the discussion is the risk of zolpidem associated adverse drug reactions as related to subjects' sex with particular focus on women. If authors found this remark meaningfull it were of an importance to the reader. I suggest the manuscript acceptance for publication in BMJO."
Many thanks for your thorough review of the manuscript and useful comments. We have now included a reference to sex-related handling of zolpidem on p14.
